Page last updated: 2024-11-04

n-methyl-dl-aspartic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

N-methyl-D-aspartic acid (NMDA) is an amino acid that acts as an agonist at the NMDA receptor, a type of glutamate receptor in the brain. NMDA receptors are involved in a variety of important brain functions, including learning and memory, synaptic plasticity, and neuronal development. NMDA receptors are also implicated in several neurological disorders, such as Alzheimer's disease, Parkinson's disease, and epilepsy. NMDA receptors are ionotropic receptors, meaning that they are directly linked to ion channels. When NMDA receptors are activated, they allow calcium ions to flow into the cell. This influx of calcium can trigger a variety of downstream signaling pathways, which are involved in the aforementioned brain functions. NMDA receptors are also involved in the phenomenon of long-term potentiation (LTP), a form of synaptic plasticity that is thought to underlie learning and memory. LTP is characterized by a long-lasting increase in the strength of synaptic connections between neurons. NMDA receptors are essential for LTP, and blocking NMDA receptors prevents the induction of LTP. The NMDA receptor is a complex protein that is composed of multiple subunits. There are four main types of subunits: NR1, NR2A, NR2B, and NR3. The NR1 subunit is essential for receptor function, and the other subunits contribute to the receptor's pharmacological properties. NMDA receptors are also subject to a variety of regulatory mechanisms, including phosphorylation, ubiquitination, and trafficking. These mechanisms help to control the activity of NMDA receptors and ensure that they are properly localized within the brain. NMDA receptors are an important target for drug development, as they are involved in a variety of neurological disorders. Drugs that target NMDA receptors are being investigated for the treatment of conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and stroke. NMDA receptors are also being investigated as potential targets for the development of new drugs for the treatment of addiction, anxiety, and depression.'

Cross-References

ID SourceID
PubMed CID4376
CHEMBL ID275325
CHEBI ID181378
SCHEMBL ID167682
MeSH IDM0222614

Synonyms (52)

Synonym
CHEMBL275325 ,
dl-aspartic acid, n-methyl-
HMS3266A05
2-(methylamino)butanedioic acid
17833-53-3
CHEBI:181378
nsc16206
nsc-16206
n-methyl-dl-aspartic acid
NCGC00095062-01
NCGC00095062-02
STK246904
AKOS005066589
bdbm50002343
NCGC00015666-02
NCGC00015666-03
unii-eu52dfc4wj
eu52dfc4wj ,
BP-12733
FT-0637610
FT-0602829
2-(methylamino)succinic acid
HMS3370L14
AB01326367-02
AM81641
SCHEMBL167682
AC-24120
methyl aspartic acid, dl-
n-methyl-dl-aspartate ,
dl-n-methylaspartic acid
mfcd00065918
2-(methylamino)succinic acid (me-dl-asp-oh)
HMS3652P20
h-d-measp-oh
n-me-asp-oh
SY035118
NCGC00015666-04
FT-0772570
BCP21209
aspartic acid,n-methyl-
HMS3675A03
DS-14547
HMS3411A03
BRD-A02508087-001-01-1
Q27277365
n-me-dl-asp-oh
EN300-6958635
DTXSID20859971
HY-W017500
n-methyl-l-aspartic acid hcl
CS-W018216
(r,s)-2-(methylamino)succinic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aspartic acid derivativeAn amino acid derivative resulting from reaction of aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of aspartic acid by a heteroatom. The definition normally excludes peptides containing aspartic acid residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency1.77830.004023.8416100.0000AID485290
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (35.00)18.2507
2000's8 (40.00)29.6817
2010's4 (20.00)24.3611
2020's1 (5.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.55 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index3.00 (0.95)

This Compound (17.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]